1. SoulierJ, GrolletL, OksenhendlerE, CacoubP, Cazals-HatemD, et al. (1995) Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86: 1276–1280.
2. ChangY, CesarmanE, PessinM, LeeF, CulpepperJ, et al. (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1865–1869.
3. CesarmanE, ChangY, MooreP, SaidJ, KnowlesD (1995) Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 18: 1186–1191.
4. VermaSC, ChoudhuriT, KaulR, RobertsonES (2006) Latency-associated nuclear antigen (LANA) of Kaposi's sarcoma-associated herpesvirus interacts with origin recognition complexes at the LANA binding sequence within the terminal repeats. J Virol 80: 2243–2256.
5. BarberaAJ, ChodaparambilJV, Kelley-ClarkeB, JoukovV, WalterJC, et al. (2006) The nucleosomal surface as a docking station for Kaposi's sarcoma herpesvirus LANA. Science 311: 856–861.
6. StedmanW, DengZ, LuF, LiebermanPM (2004) ORC, MCM, and histone hyperacetylation at the Kaposi's sarcoma-associated herpesvirus latent replication origin. J Virol 78: 12566–12575.
7. KrithivasA, FujimuroM, WeidnerM, YoungDB, HaywardSD (2002) Protein interactions targeting the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus to cell chromosomes. J Virol 76: 11596–11604.
8. PiolotT, TramierM, CoppeyM, NicolasJC, MarechalV (2001) Close but distinct regions of human herpesvirus 8 latency-associated nuclear antigen 1 are responsible for nuclear targeting and binding to human mitotic chromosomes. J Virol 75: 3948–3959.
9. CotterMA2nd, RobertsonES (1999) The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells. Virology 264: 254–264.
10. BallestasME, ChatisPA, KayeKM (1999) Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 284: 641–644.
11. GrundhoffA, GanemD (2003) The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus permits replication of terminal repeat-containing plasmids. J Virol 77: 2779–2783.
12. HuJ, GarberAC, RenneR (2002) The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus supports latent DNA replication in dividing cells. J Virol 76: 11677–11687.
13. GarberAC, HuJ, RenneR (2002) Latency-associated nuclear antigen (LANA) cooperatively binds to two sites within the terminal repeat, and both sites contribute to the ability of LANA to suppress transcription and to facilitate DNA replication. J Biol Chem 277: 27401–27411.
14. GuntherT, GrundhoffA (2010) The epigenetic landscape of latent Kaposi sarcoma-associated herpesvirus genomes. PLoS Pathog 6: e1000935.
15. TothZ, MaglinteDT, LeeSH, LeeHR, WongLY, et al. (2010) Epigenetic analysis of KSHV latent and lytic genomes. PLoS Pathog 6: e1001013.
16. DarstRP, HaeckerI, PardoCE, RenneR, KladdeMP (2013) Epigenetic diversity of Kaposi's sarcoma-associated herpesvirus. Nucleic Acids Res 41: 2993–3009.
17. HiltonIB, SimonJM, LiebJD, DavisIJ, DamaniaB, et al. (2013) The open chromatin landscape of Kaposi's sarcoma-associated herpesvirus. J Virol 87: 11831–11842.
18. TothZ, BruloisK, LeeHR, IzumiyaY, TepperC, et al. (2013) Biphasic Euchromatin-to-Heterochromatin Transition on the KSHV Genome Following De Novo Infection. PLoS Pathog 9: e1003813.
19. MargueronR, JustinN, OhnoK, SharpeML, SonJ, et al. (2009) Role of the polycomb protein EED in the propagation of repressive histone marks. Nature 461: 762–767.
20. MargueronR, ReinbergD (2011) The Polycomb complex PRC2 and its mark in life. Nature 469: 343–349.
21. HansenKH, BrackenAP, PasiniD, DietrichN, GehaniSS, et al. (2008) A model for transmission of the H3K27me3 epigenetic mark. Nature cell biology 10: 1291–1300.
22. HansenKH, HelinK (2009) Epigenetic inheritance through self-recruitment of the polycomb repressive complex 2. Epigenetics : official journal of the DNA Methylation Society 4: 133–138.
23. BrownJL, KassisJA (2013) Architectural and functional diversity of polycomb group response elements in Drosophila. Genetics 195: 407–419.
24. SonJ, ShenSS, MargueronR, ReinbergD (2013) Nucleosome-binding activities within JARID2 and EZH1 regulate the function of PRC2 on chromatin. Genes Dev 27: 2663–2677.
25. BasuA, WilkinsonFH, ColavitaK, FennellyC, AtchisonML (2013) YY1 DNA binding and interaction with YAF2 is essential for Polycomb recruitment. Nucleic Acids Res 8: 2208–2223.
26. SchorderetP, LonfatN, DarbellayF, TschoppP, GittoS, et al. (2013) A genetic approach to the recruitment of PRC2 at the HoxD locus. PLoS Genet 9: e1003951.
27. KanekoS, BonasioR, Saldana-MeyerR, YoshidaT, SonJ, et al. (2014) Interactions between JARID2 and Noncoding RNAs Regulate PRC2 Recruitment to Chromatin. Mol Cell 53: 290–300.
28. TavaresL, DimitrovaE, OxleyD, WebsterJ, PootR, et al. (2012) RYBP-PRC1 complexes mediate H2A ubiquitylation at polycomb target sites independently of PRC2 and H3K27me3. Cell 148: 664–678.
29. HeJ, ShenL, WanM, TaranovaO, WuH, et al. (2013) Kdm2b maintains murine embryonic stem cell status by recruiting PRC1 complex to CpG islands of developmental genes. Nat Cell Biol 15: 373–384.
30. WuX, JohansenJV, HelinK (2013) Fbxl10/Kdm2b recruits polycomb repressive complex 1 to CpG islands and regulates H2A ubiquitylation. Mol Cell 49: 1134–1146.
31. BarreroMJ, Izpisua BelmonteJC (2013) Polycomb complex recruitment in pluripotent stem cells. Nat Cell Biol 15: 348–350.
32. BechtelJT, WinantRC, GanemD (2005) Host and viral proteins in the virion of Kaposi's sarcoma-associated herpesvirus. Journal of virology 79: 4952–4964.
33. Lallemand-BreitenbachV, ZhuJ, PuvionF, KokenM, HonoreN, et al. (2001) Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med 193: 1361–1371.
34. LiH, LeoC, ZhuJ, WuX, O'NeilJ, et al. (2000) Sequestration and inhibition of Daxx-mediated transcriptional repression by PML. Mol Cell Biol 20: 1784–1796.
35. ZhongS, SalomoniP, PandolfiPP (2000) The transcriptional role of PML and the nuclear body. Nat Cell Biol 2: E85–90.
36. PearsonM, CarboneR, SebastianiC, CioceM, FagioliM, et al. (2000) PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406: 207–210.
37. FerbeyreG, de StanchinaE, QueridoE, BaptisteN, PrivesC, et al. (2000) PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 14: 2015–2027.
38. BischofO, KirshO, PearsonM, ItahanaK, PelicciPG, et al. (2002) Deconstructing PML-induced premature senescence. EMBO J 21: 3358–3369.
39. LangleyE, PearsonM, FarettaM, BauerUM, FryeRA, et al. (2002) Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 21: 2383–2396.
40. SalomoniP, FergusonBJ, WyllieAH, RichT (2008) New insights into the role of PML in tumour suppression. Cell Res 18: 622–640.
41. SalomoniP, PandolfiPP (2002) The role of PML in tumor suppression. Cell 108: 165–170.
42. BischofO, KimSH, IrvingJ, BerestenS, EllisNA, et al. (2001) Regulation and localization of the Bloom syndrome protein in response to DNA damage. J Cell Biol 153: 367–380.
43. CarboneR, PearsonM, MinucciS, PelicciPG (2002) PML NBs associate with the hMre11 complex and p53 at sites of irradiation induced DNA damage. Oncogene 21: 1633–1640.
44. Krieghoff-HenningE, HofmannTG (2008) Role of nuclear bodies in apoptosis signalling. Biochim Biophys Acta 1783: 2185–2194.
45. WangZG, RuggeroD, RonchettiS, ZhongS, GaboliM, et al. (1998) PML is essential for multiple apoptotic pathways. Nat Genet 20: 266–272.
46. HofmannTG, WillH (2003) Body language: the function of PML nuclear bodies in apoptosis regulation. Cell Death Differ 10: 1290–1299.
47. FogalV, GostissaM, SandyP, ZacchiP, SternsdorfT, et al. (2000) Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J 19: 6185–6195.
48. TorokD, ChingRW, Bazett-JonesDP (2009) PML nuclear bodies as sites of epigenetic regulation. Front Biosci 14: 1325–1336.
49. EverettRD (2001) DNA viruses and viral proteins that interact with PML nuclear bodies. Oncogene 20: 7266–7273.
50. EverettRD, Chelbi-AlixMK (2007) PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89: 819–830.
51. TavalaiN, StammingerT (2008) New insights into the role of the subnuclear structure ND10 for viral infection. Biochim Biophys Acta 1783: 2207–2221.
52. ShimodaK, KamesakiK, NumataA, AokiK, MatsudaT, et al. (2002) Cutting edge: tyk2 is required for the induction and nuclear translocation of Daxx which regulates IFN-alpha-induced suppression of B lymphocyte formation. J Immunol 169: 4707–4711.
53. GrotzingerT, SternsdorfT, JensenK, WillH (1996) Interferon-modulated expression of genes encoding the nuclear-dot-associated proteins Sp100 and promyelocytic leukemia protein (PML). Eur J Biochem 238: 554–560.
54. StadlerM, Chelbi-AlixMK, KokenMH, VenturiniL, LeeC, et al. (1995) Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene 11: 2565–2573.
55. Van DammeE, Van OstadeX (2011) Crosstalk between viruses and PML nuclear bodies: a network-based approach. Front Biosci (Landmark Ed) 16: 2910–2920.
56. Chelbi-AlixMK, QuignonF, PelicanoL, KokenMHM, de ThéH (1998) Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein. J Virol 72: 1043–1051.
57. RegadT, SaibA, Lallemand-BreitenbachV, PandolfiPP, de TheH, et al. (2001) PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator. EMBO J 20: 3495–3505.
58. ChangJY, LiL, FanYH, MuZM, ZhangWW, et al. (1997) Cell-cycle regulation of DNA-damage-induced expression of the suppressor gene PML. Biochem Biophys Res Commun 240: 640–646.
59. IshovAM, SotnikovAG, NegorevD, VladimirovaOV, NeffN, et al. (1999) PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J Cell Biol 147: 221–234.
60. ShenTH, LinHK, ScaglioniPP, YungTM, PandolfiPP (2006) The mechanisms of PML-nuclear body formation. Mol Cell 24: 331–339.
61. BernardiR, PandolfiPP (2007) Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 8: 1006–1016.
62. NegorevD, MaulGG (2001) Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene 20: 7234–7242.
63. AscoliCA, MaulGG (1991) Identification of a novel nuclear domain. J Cell Biol 112: 785–795.
64. DyckJA, MaulGG, MillerWJ, ChenJD, KakizukaA, et al. (1994) A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 78: 799–811.
65. HodgesM, TissotC, HoweK, GrimwadeD, FreemontPS (1998) Structure, organization, and dynamics of promyelocytic leukemia protein nuclear bodies. Am J Hum Genet 63: 297–304.
66. KokenMH, Puvion-DutilleulF, GuilleminMC, VironA, Linares-CruzG, et al. (1994) The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J 13: 1073–1083.
67. MelnickA, FruchtmanS, ZelentA, LiuM, HuangQ, et al. (1999) Identification of novel chromosomal rearrangements in acute myelogenous leukemia involving loci on chromosome 2p23, 15q22 and 17q21. Leukemia 13: 1534–1538.
68. MelnickA, LichtJD (1999) Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93: 3167–3215.
69. Plehn-DujowichD, BellP, IshovAM, BaumannC, MaulGG (2000) Non-apoptotic chromosome condensation induced by stress: delineation of interchromosomal spaces. Chromosoma 109: 266–279.
70. WeisK, RambaudS, LavauC, JansenJ, CarvalhoT, et al. (1994) Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell 76: 345–356.
71. Van DammeE, LaukensK, DangTH, Van OstadeX (2010) A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics. Int J Biol Sci 6: 51–67.
72. ZhongS, MullerS, RonchettiS, FreemontPS, DejeanA, et al. (2000) Role of SUMO-1-modified PML in nuclear body formation. Blood 95: 2748–2752.
73. ChingRW, DellaireG, EskiwCH, Bazett-JonesDP (2005) PML bodies: a meeting place for genomic loci? J Cell Sci 118: 847–854.
74. DellaireG, Bazett-JonesDP (2004) PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. BioEssays 26: 963–977.
75. LangM, JegouT, ChungI, RichterK, MünchS, et al. (2010) Three-dimensional organization of promyelocytic leukemia nuclear bodies. J Cell Sci 123: 392–400.
76. BoddyMN, HoweK, EtkinLD, SolomonE, FreemontPS (1996) PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene 13: 971–982.
77. MahajanR, DelphinC, GuanT, GeraceL, MelchiorF (1997) A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell 88: 97–107.
78. MatunisMJ, CoutavasE, BlobelG (1996) A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J Cell Biol 135: 1457–1470.
79. MeluhPB, KoshlandD (1995) Evidence that the MIF2 gene of Saccharomyces cerevisiae encodes a centromere protein with homology to the mammalian centromere protein CENP-C. Mol Biol Cell 6: 793–807.
80. OkuraT, GongL, KamitaniT, WadaT, OkuraI, et al. (1996) Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J Immunol 157: 4277–4281.
81. ShenZ, Pardington-PurtymunPE, ComeauxJC, MoyzisRK, ChenDJ (1996) UBL1, a human ubiquitin-like protein associating with human RAD51/RAD52 proteins. Genomics 36: 271–279.
82. SaitohH, HincheyJ (2000) Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem 275: 6252–6258.
83. OwerbachD, McKayEM, YehET, GabbayKH, BohrenKM (2005) A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. Biochem Biophys Res Commun 332: 517–520.
84. NefkensI, NegorevDG, IshovAM, MichaelsonJS, YehET, et al. (2003) Heat shock and Cd2+ exposure regulate PML and Daxx release from ND10 by independent mechanisms that modify the induction of heat-shock proteins 70 and 25 differently. J Cell Sci 116: 513–524.
85. BordenKL (2002) Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Mol Cell Biol 22: 5259–5269.
86. Marcos-VillarL, Lopitz-OtsoaF, GallegoP, Munoz-FontelaC, Gonzalez-SantamariaJ, et al. (2009) Kaposi's sarcoma-associated herpesvirus protein LANA2 disrupts PML oncogenic domains and inhibits PML-mediated transcriptional repression of the survivin gene. Journal of virology 83: 8849–8858.
87. Marcos-VillarL, CampagnaM, Lopitz-OtsoaF, GallegoP, Gonzalez-SantamariaJ, et al. (2011) Covalent modification by SUMO is required for efficient disruption of PML oncogenic domains by Kaposi's sarcoma-associated herpesvirus latent protein LANA2. The Journal of general virology 92: 188–194.
88. KatanoH, Ogawa-GotoK, HasegawaH, KurataT, SataT (2001) Human-herpesvirus-8-encoded K8 protein colocalizes with the promyelocytic leukemia protein (PML) bodies and recruits p53 to the PML bodies. Virology 286: 446–455.
89. FullF, JungnicklD, ReuterN, BognerE, BruloisK, et al. (2014) Kaposi's Sarcoma Associated Herpesvirus Tegument Protein ORF75 Is Essential for Viral Lytic Replication and Plays a Critical Role in the Antagonization of ND10-Instituted Intrinsic Immunity. PLoS Pathog 10: e1003863.
90. NewhartA, NegorevDG, Rafalska-MetcalfIU, YangT, MaulGG, et al. (2013) Sp100A promotes chromatin decondensation at a cytomegalovirus-promoter-regulated transcription site. Molecular biology of the cell 24: 1454–1468.
91. GrundhoffA, GanemD (2004) Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest 113: 124–136.
92. ChandrianiS, GanemD (2010) Array-based transcript profiling and limiting-dilution reverse transcription-PCR analysis identify additional latent genes in Kaposi's sarcoma-associated herpesvirus. J Virol 84: 5565–5573.
93. AriasC, WeisburdB, Stern-GinossarN, MercierA, MadridAS, et al. (2014) KSHV 2.0: A Comprehensive Annotation of the Kaposi's Sarcoma-Associated Herpesvirus Genome Using Next-Generation Sequencing Reveals Novel Genomic and Functional Features. PLoS Pathog 10: e1003847.
94. XiaoB, VermaSC, CaiQ, KaulR, LuJ, et al. (2010) Bub1 and CENP-F can contribute to Kaposi's sarcoma-associated herpesvirus genome persistence by targeting LANA to kinetochores. J Virol 84: 9718–9732.
95. SzekelyL, KissC, MattssonK, KashubaE, PokrovskajaK, et al. (1999) Human herpesvirus-8-encoded LNA-1 accumulates in heterochromatin- associated nuclear bodies. J Gen Virol 80 (Pt 11) 2889–2900.
96. PozharskayaVP, WeaklandLL, ZimringJC, KrugLT, UngerER, et al. (2004) Short duration of elevated vIRF-1 expression during lytic replication of human herpesvirus 8 limits its ability to block antiviral responses induced by alpha interferon in BCBL-1 cells. J Virol 78: 6621–6635.
97. FullF, ReuterN, ZielkeK, StammingerT, EnsserA (2012) Herpesvirus saimiri antagonizes nuclear domain 10-instituted intrinsic immunity via an ORF3-mediated selective degradation of cellular protein Sp100. J Virol 86: 3541–3553.
98. Viejo-BorbollaA, KatiE, SheldonJA, NathanK, MattssonK, et al. (2003) A Domain in the C-terminal region of latency-associated nuclear antigen 1 of Kaposi's sarcoma-associated Herpesvirus affects transcriptional activation and binding to nuclear heterochromatin. J Virol 77: 7093–7100.
99. LuF, DayL, GaoSJ, LiebermanPM (2006) Acetylation of the latency-associated nuclear antigen regulates repression of Kaposi's sarcoma-associated herpesvirus lytic transcription. Journal of virology 80: 5273–5282.
100. LanK, KuppersDA, VermaSC, RobertsonES (2004) Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen inhibits lytic replication by targeting Rta: a potential mechanism for virus-mediated control of latency. Journal of virology 78: 6585–6594.
101. EverettRD, ParadaC, GriponP, SirmaH, OrrA (2008) Replication of ICP0-null mutant herpes simplex virus type 1 is restricted by both PML and Sp100. J Virol 82: 2661–2672.
102. LukashchukV, EverettRD (2010) Regulation of ICP0-null mutant herpes simplex virus type 1 infection by ND10 components ATRX and hDaxx. J Virol 84: 4026–4040.
103. MichaelsonJS, LederP (2003) RNAi reveals anti-apoptotic and transcriptionally repressive activities of DAXX. J Cell Sci 116: 345–352.
104. SchreinerS, WimmerP, SirmaH, EverettRD, BlanchetteP, et al. (2010) Proteasome-dependent degradation of Daxx by the viral E1B-55K protein in human adenovirus-infected cells. J Virol 84: 7029–7038.
105. SchreinerS, BurckC, GlassM, GroitlP, WimmerP, et al. (2013) Control of human adenovirus type 5 gene expression by cellular Daxx/ATRX chromatin-associated complexes. Nucleic Acids Res 41: 3532–3550.
106. UllmanAJ, HearingP (2008) Cellular proteins PML and Daxx mediate an innate antiviral defense antagonized by the adenovirus E4 ORF3 protein. J Virol 82: 7325–7335.
107. PrasadA, RemickJ, ZeichnerSL (2013) Activation of Human Herpesvirus Replication by Apoptosis. J Virol 87: 10641–10650.
108. TavalaiN, StammingerT (2009) Interplay between Herpesvirus Infection and Host Defense by PML Nuclear Bodies. Viruses 1: 1240–1264.
109. TorokD, ChingRW, Bazett-JonesDP (2009) PML nuclear bodies as sites of epigenetic regulation. Frontiers in bioscience 14: 1325–1336.
110. ChandranB (2010) Early events in Kaposi's sarcoma-associated herpesvirus infection of target cells. J Virol 84: 2188–2199.
111. SathishN, YuanY (2011) Evasion and subversion of interferon-mediated antiviral immunity by Kaposi's sarcoma-associated herpesvirus: an overview. J Virol 85: 10934–10944.
112. CampbellM, IzumiyaY (2012) Post-Translational Modifications of Kaposi's Sarcoma-Associated Herpesvirus Regulatory Proteins - SUMO and KSHV. Frontiers in microbiology 3: 31.
113. CaiQ, CaiS, ZhuC, VermaSC, ChoiJ-Y, et al. (2013) A Unique SUMO-2-Interacting Motif within LANA Is Essential for KSHV Latency. PLoS pathogens 9: e1003750.
114. IzumiyaY, KobayashiK, KimKY, PochampalliM, IzumiyaC, et al. (2013) Kaposi's Sarcoma-Associated Herpesvirus K-Rta Exhibits SUMO-Targeting Ubiquitin Ligase (STUbL) Like Activity and Is Essential for Viral Reactivation. PLoS Pathog 9: e1003506.
115. OhsakiE, SuzukiT, KarayamaM, UedaK (2009) Accumulation of LANA at nuclear matrix fraction is important for Kaposi's sarcoma-associated herpesvirus replication in latency. Virus Res 139: 74–84.
116. KrishnanHH, NaranattPP, SmithMS, ZengL, BloomerC, et al. (2004) Concurrent expression of latent and a limited number of lytic genes with immune modulation and antiapoptotic function by Kaposi's sarcoma-associated herpesvirus early during infection of primary endothelial and fibroblast cells and subsequent decline of lytic gene expression. J Virol 78: 3601–3620.
117. IsaacA, WilcoxKW, TaylorJL (2006) SP100B, a repressor of gene expression preferentially binds to DNA with unmethylated CpGs. J Cell Biochem 98: 1106–1122.
118. LingPD, PengRS, NakajimaA, YuJH, TanJ, et al. (2005) Mediation of Epstein-Barr virus EBNA-LP transcriptional coactivation by Sp100. The EMBO journal 24: 3565–3575.
119. AndertonJA, BoseS, VockerodtM, VrzalikovaK, WeiW, et al. (2011) The H3K27me3 demethylase, KDM6B, is induced by Epstein-Barr virus and over-expressed in Hodgkin's Lymphoma. Oncogene 30: 2037–2043.
120. CallahanJ, PaiS, CotterM, RobertsonES (1999) Distinct patterns of viral antigen expression in Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus coinfected body-cavity-based lymphoma cell lines: potential switches in latent gene expression due to coinfection. Virology 262: 18–30.
121. HorensteinMG, NadorRG, ChadburnA, HyjekEM, InghiramiG, et al. (1997) Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. Blood 90: 1186–1191.
122. YuM, MazorT, HuangH, HuangHT, KathreinKL, et al. (2012) Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors. Mol Cell 45: 330–343.
123. FarcasAM, BlackledgeNP, SudberyI, LongHK, McGouranJF, et al. (2012) KDM2B links the Polycomb Repressive Complex 1 (PRC1) to recognition of CpG islands. Elife 1: e00205.
124. HerndierBG, WernerA, ArnsteinP, AbbeyNW, DemartisF, et al. (1994) Characterization of a human Kaposi's sarcoma cell line that induces angiogenic tumors in animals. Aids 8: 575–581.
125. EdgellCJ, McDonaldCC, GrahamJB (1983) Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci U S A 80: 3734–3737.
126. GrahamFL, SmileyJ, RussellWC, NairnR (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36: 59–74.
127. RenneR, ZhongW, HerndierB, McGrathM, AbbeyN, et al. (1996) Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med 2: 342–346.
128. CarboneA, CiliaAM, GloghiniA, CapelloD, TodescoM, et al. (1998) Establishment and characterization of EBV-positive and EBV-negative primary effusion lymphoma cell lines harbouring human herpesvirus type-8. Br J Haematol 102: 1081–1089.
129. UphoffCC, CarboneA, GaidanoG, DrexlerHG (1998) HHV-8 infection is specific for cell lines derived from primary effusion (body cavity-based) lymphomas. Leukemia 12: 1806–1809.
130. PulvertaftJV (1965) A Study of Malignant Tumours in Nigeria by Short-Term Tissue Culture. J Clin Pathol 18: 261–273.
131. PulvertaftJV (1964) Cytology of Burkitt's Tumour (African Lymphoma). Lancet 1: 238–240.
132. MenezesJ, LeiboldW, KleinG, ClementsG (1975) Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine/[publiee pour l'AAICIG] 22: 276–284.
133. KitamuraT, KoshinoY, ShibataF, OkiT, NakajimaH, et al. (2003) Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Experimental hematology 31: 1007–1014.
134. LeppardKN, ShenkT (1989) The adenovirus E1B 55 kd protein influences mRNA transport via an intranuclear effect on RNA metabolism. Embo J 8: 2329–2336.
135. SchreinerS, MartinezR, GroitlP, RayneF, VaillantR, et al. (2012) Transcriptional activation of the adenoviral genome is mediated by capsid protein VI. PLoS Pathog 8: e1002549.
136. SternsdorfT, JensenK, WillH (1997) Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. J Cell Biol 139: 1621–1634.
137. RenneR, BarryC, DittmerD, CompitelloN, BrownPO, et al. (2001) Modulation of cellular and viral gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. Journal of virology 75: 458–468.
138. RodriguezMS, DesterroJM, LainS, MidgleyCA, LaneDP, et al. (1999) SUMO-1 modification activates the transcriptional response of p53. The EMBO journal 18: 6455–6461.
139. TrapnellC, PachterL, SalzbergSL (2009) TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25: 1105–1111.
140. KimD, PerteaG, TrapnellC, PimentelH, KelleyR, et al. (2013) TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome biology 14: R36.
141. TrapnellC, RobertsA, GoffL, PerteaG, KimD, et al. (2012) Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nature protocols 7: 562–578.
142. TrapnellC, HendricksonDG, SauvageauM, GoffL, RinnJL, et al. (2013) Differential analysis of gene regulation at transcript resolution with RNA-seq. Nature biotechnology 31: 46–53.
143. BruloisKF, ChangH, LeeAS, EnsserA, WongLY, et al. (2012) Construction and manipulation of a new Kaposi's sarcoma-associated herpesvirus bacterial artificial chromosome clone. Journal of virology 86: 9708–9720.